Inventor
HAMBURGER AGNES EVA
US28 patents
⚠️ This page may combine multiple inventors who share the name “HAMBURGER AGNES EVA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
AMGEN INC
22 patentsUS8034770B2Oct 11, 2011
FGF21 polypeptides comprising two or more mutations
AMGEN INC63 citations99
US8361963B2Jan 29, 2013
Uses of FGF21 polypeptides comprising two or more mutations
AMGEN INC64 citations98
US9365653B2Jun 14, 2016
Human PAC1 antibodies
AMGEN INC24 citations94
US9273106B2Mar 1, 2016
FGF mutants with reduced proteolysis and aggregation
AMGEN INC9 citations92
US9862752B2Jan 9, 2018
Growth differentiation factor 15 (GDF-15) constructs
AMGEN INC16 citations91
US9714276B2Jul 25, 2017
Growth differentiation factor 15 (GDF-15) polypeptides
AMGEN INC17 citations91
US11072640B2Jul 27, 2021
Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
AMGEN INC3 citations84
US10053507B2Aug 21, 2018
Human PAC1 antibodies
AMGEN INC6 citations84
US10011642B2Jul 3, 2018
Methods of treating of diabetes and obesity using FGF21 mutants
AMGEN INC4 citations84
US9822178B2Nov 21, 2017
Human PAC1 antibodies
AMGEN INC6 citations84
US9676851B2Jun 13, 2017
Human PAC1 antibodies
AMGEN INC6 citations84
US9493530B2Nov 15, 2016
FGF21 mutants comprising a mutation at position 98, 171 and/or 180
AMGEN INC10 citations84
US10336798B2Jul 2, 2019
Growth differentiation factor 15 (GDF-15) polypeptides
AMGEN INC9 citations83
US11739131B2Aug 29, 2023
Growth differentiation factor 15 (GDF-15) polypeptides
AMGEN INC1 citations72
US11891435B2Feb 6, 2024
Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof
AMGEN INC1 citations71
US11248043B2Feb 15, 2022
Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof
AMGEN INC1 citations71
US10894814B2Jan 19, 2021
Growth differentiation factor 15 (GDF-15) constructs
AMGEN INC4 citations71
US10738110B2Aug 11, 2020
PAC1 antibodies and uses thereof
AMGEN INC3 citations71
US11840558B2Dec 12, 2023
Methods of treating non-alcoholic steatohepatitis using FGF21 mutants
AMGEN INC0 citations62
US10793631B2Oct 6, 2020
Human PAC1 antibodies
AMGEN INC0 citations52
US10472417B2Nov 12, 2019
Human PAC1 antibodies
AMGEN INC0 citations52
US10294298B2May 21, 2019
Human PAC1 antibodies
AMGEN INC0 citations52
BELOUSKI EDWARD JOHN
6 patentsUS8835385B2Sep 16, 2014
FGF21 polypeptides comprising two or more mutations and uses thereof
BELOUSKI EDWARD JOHN48 citations97
US8795985B2Aug 5, 2014
FGF 21 polypeptides comprising two or more mutations and uses thereof
BELOUSKI EDWARD JOHN48 citations97
US8642546B2Feb 4, 2014
FGF21 mutant fusion polypeptides and uses thereof
BELOUSKI EDWARD JOHN64 citations97
US8618053B2Dec 31, 2013
FGF21 mutants multimers and uses thereof
BELOUSKI EDWARD JOHN45 citations97
US8410051B2Apr 2, 2013
FGF21 mutants and uses thereof
BELOUSKI EDWARD JOHN63 citations97
US8188040B2May 29, 2012
FGF21 mutants and uses thereof
BELOUSKI EDWARD JOHN59 citations97